Second transmyocardial revascularisation (TMR) system enters trials
This article was originally published in Clinica
Executive Summary
Cornell University is to conduct pre-clinical trials of Helionetics' (US) excimer laser transmyocardial revascularisation (TMR) system. The Cornell researchers, led by Dr Todd Rosengart, hope to generate sufficient safety channel patency data to submit an IDE for clinical trials in early 1996. The laser system has been developed by Helionetics' subsidiary Laser Photonics/AccuLase. PLC Medical Systems' Heart Laser, a CO(2) system, received an IDE for US trials in February (see Clinica No 642, p 20) and has been granted expedited review status.